f750408a-8999-400e-8ef3-6e2200a2df9a_6085_-_jason_long_v2.pdf (1.65 MB)
Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry
journal contribution
posted on 2023-06-09, 11:56 authored by Jason Long, Edward WrightEdward Wright, Eleonora Molesti, Nigel Temperton, Wendy BarclayEmerging viral diseases pose a threat to the global population as intervention strategies are mainly limited to basic containment due to the lack of efficacious and approved vaccines and antiviral drugs. The former was the only available intervention when the current unprecedented Ebolavirus (EBOV) outbreak in West Africa began. Prior to this, the development of EBOV vaccines and anti-viral therapies required time and resources that were not available. Therefore, focus has turned to re-purposing of existing, licenced medicines that may limit the morbidity and mortality rates of EBOV and could be used immediately. Here we test three such medicines and measure their ability to inhibit pseudotype viruses (PVs) of two EBOV species, Marburg virus (MARV) and avian influenza H5 (FLU-H5). We confirm the ability of chloroquine (CQ) to inhibit viral entry in a pH specific manner. The commonly used proton pump inhibitors, Omeprazole and Esomeprazole were also able to inhibit entry of all PVs tested but at higher drug concentrations than may be achieved in vivo. We propose CQ as a priority candidate to consider for treatment of EBOV.
History
Publication status
- Published
File Version
- Published version
Journal
F1000ResearchISSN
2046-1402Publisher
F1000ResearchExternal DOI
Issue
30Volume
4Department affiliated with
- Biochemistry Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2018-02-07First Open Access (FOA) Date
2018-02-07First Compliant Deposit (FCD) Date
2018-02-06Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC